Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3NSU0
|
|||
| Drug Name |
KPL-404
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20; ICD-9: 729] | Phase 2 | [1] | |
| Company |
Kiniksa Pharmaceuticals Lexington, MA
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05198310) A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor. U.S.National Institutes of Health. | |||
| REF 2 | Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients. Arthritis Res Ther. 2021 Jan 6;23(1):5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.